| 谢婷婷,郭代红,高奥,等.德曲妥珠单抗相关不良反应文献分析[J].安徽医药,2025,29(2):417-420. |
| 德曲妥珠单抗相关不良反应文献分析 |
| Adverse reactions related to trastuzumab deruxtecan:a literature analysis |
| |
| DOI：10.3969/j.issn.1009-6469.2025.02.043 |
| 中文关键词: 抗体，单克隆 德曲妥珠单抗 乳腺癌 药品不良反应 文献分析 |
| 英文关键词: Antibodies,monoclonal Trastuzumab deruxtecan Breast cancer Adverse drug reaction Literature analysis |
| 基金项目:中国研究型医院学会专项课题项目 -临床重点药品的使用监测和评价研究专项( Y2024FH-YWPJ02-102) |
|
| 摘要点击次数: 884 |
| 全文下载次数: 335 |
| 中文摘要: |
| 目的分析德曲妥珠单抗相关不良反应(ADR)的发生情况及临床特点，为临床安全用药提供参考。方法通过检索中国知网、万方、维普、超星、 PubMed、Embase数据库，筛选该药致不良反应的案例报道，对病人的一般资料、用药情况及不良反应发生特点等进行统计分析。结果根据文献纳入与排除标准，共筛选出有效文献 12篇，涉及病例 23例，病人年龄 54.2岁( 38 ~ 80岁)，原患疾病主要为乳腺癌、非小细胞肺癌、胃腺癌伴各种部位转移。德曲妥珠单抗所致 ADR发生时间为 38 d(7d至 4个月)，ADR累及系统 /器官主要为血液系统( 24.44%)、全身整体疾病( 22.22%)及呼吸系统( 15.56%)。发生 ADR后， 23例均及时给予停药， 21例( 91.30%)在给予对症治疗后症状好转， 2例死亡。结论使用德曲妥珠单抗治疗前应做好病人的用药评估，重视 ADR监测，治疗期间应密切监测病人肺功能、心功能指标，一旦发生 ADR，及时采取干预措施，确保病人用药安全。 |
| 英文摘要: |
| Objective To analyze the occurrence and clinical characteristics of adverse reactions (ADR) related to trastuzumab derux-tecan, and provide reference for rational drug use in clinical practice. Methods By retrieval in databases such as CNKI, Wanfang,VIP, Chaoxing, PubMed, and Embase, case reports of adverse reactions caused by trastuzumab deruxtecan were screened, and statisti-cal analysis was conducted on the general information, medication situation, and characteristics of adverse reactions of patients.Results According to the inclusion and exclusion criteria of literature, a total of 12 valid literature were screened out, involving 23cases with an average age of 54.2 years (38~80 years). The primary diseases were mainly breast cancer, non-small cell lung cancer, andgastric adenocarcinoma with various site metastases. The average occurrence time of ADR caused by trastuzumab deruxtecan was 38 d(7 d to 4 months). ADR mainly affected the blood system (24.44%), systemic diseases (22.22%), and respiratory system (15.56%). Afterthe occurrence of ADR, 23 patients promptly stopped taking medication, 21 (91.30%) patients showed improvement in symptoms afterreceiving symptomatic treatment, and 2 patients died.Conclusions Before using trastuzumab deruxtecan for treatment, the patient'smedication evaluation should be performed, and ADR monitoring should be emphasized. During the treatment period, a patient's lungand heart function indicators should be closely monitored. Once ADR occurs, timely intervention measures should be taken to ensuremedication safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
